Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Inflamm Bowel Dis ; 2022 Aug 16.
Article in English | MEDLINE | ID: covidwho-2313026

ABSTRACT

This prospective case-control study investigated the impact of severe acute respiratory syndrome coronavirus 2 infection on inflammatory bowel disease course and looked for risk factors associated with flares. In the severe acute respiratory syndrome coronavirus 2 pandemic era, inflammatory bowel disease course is not influenced by infection, while therapy discontinuation is a risk factor for disease flare.

2.
Minerva Med ; 2022 Mar 22.
Article in English | MEDLINE | ID: covidwho-2312168

ABSTRACT

The newly described SARS-CoV-2 respiratory virus is now righteously presenting as an ominous threat, based on the speed with which it originated a zoonosis from bats; advancing at a similar rate, the virus has placed mankind before a pandemic, with an infection toll of some 431 million, and a lethality of 5,9 million (as of 25 February 2022). The size of the harm that this agent can unleash against us is appallingly wide, from brain ischemia to foot chilblain, passing by heart massive infarction. Designing a possible response, we reappraised the well-known equation depression-inflammation, and tested the hypothesis that an upgraded ease-of-mind might help reduce the host's hospitality towards SARS-CoV-2. With time passing, it becomes increasingly evident that the virus shall tend to progressively occupy spaces, replacing pandemics with an apparently calm endemicity. This will have to be avoided, and surveillance of society on psychological terms will be one tenet. Needless to say, the role of the enteric tract in these issues is growing higher, and it will be narrated to seal the matters with the last (not the least) touch of glue.

4.
Minerva Med ; 112(1): 144-152, 2021 Feb.
Article in English | MEDLINE | ID: covidwho-890934

ABSTRACT

The world is now entering its 9th month of combat against a pandemic of deadly pneumonia. Started out from China in December 2019, the disease has been declared as caused by infection with a so far unknown RNA Coronavirus of the respiratory family, then named severe acute respiratory syndrome coronavirus SARS-CoV-2. In the absence of a vaccine, and with scientists still struggling for an effective therapy, COVID-19 (the SARS-dependent syndrome) carries up to now, a death toll of more than 590,000 (July 18,2020) undermining jobs and finance of contemporary society in all continents. Social distancing, the only measure hitherto shown to restrain virus spread, has been progressively loosened from May 2020 in some countries, leaving us in the fear of repeat attacks from the unchecked virus. We discuss the problem and propose to tentatively boost the antivirus cell machinery by using lab-made viral mimics to engage cell receptors.


Subject(s)
COVID-19/therapy , SARS-CoV-2 , COVID-19/complications , COVID-19/epidemiology , Carboxymethylcellulose Sodium/analogs & derivatives , Carboxymethylcellulose Sodium/therapeutic use , Cytokine Release Syndrome/etiology , Humans , Immunization, Passive , Interferon Inducers/therapeutic use , Mucocutaneous Lymph Node Syndrome/etiology , Physical Distancing , Poly I-C/therapeutic use , Polylysine/analogs & derivatives , Polylysine/therapeutic use , Practice Guidelines as Topic , RNA, Double-Stranded/drug effects , RNA, Viral/drug effects , Recurrence , SARS-CoV-2/classification , SARS-CoV-2/genetics , SARS-CoV-2/pathogenicity , Secondary Prevention , COVID-19 Drug Treatment , COVID-19 Serotherapy
SELECTION OF CITATIONS
SEARCH DETAIL